Merck (MRK) Q2 2026 earnings review
Revenue Beats, but Aggressive Pipeline Shopping Obliterates the Bottom Line
Merck delivered solid 5% top-line growth ($16.6B) driven by a stable Keytruda franchise and a hyper-scaling Winrevair. However, earnings completely decoupled from operations as management booked a massive $5.7 billion charge for the Terns acquisition. This follows last quarter's $9.0 billion Cidara charge, plunging Q2 non-GAAP EPS into the red (-$0.13) and forcing a drastic 46% cut to the midpoint of FY26 EPS guidance. The operational story remains intact—the post-Keytruda pipeline is taking shape with new launches outperforming—but the staggering price tag for this transformation is wiping out shareholder profitability in the near term.
🐂 Bull Case
The PAH drug grew 75% YoY to $588M. It is scaling rapidly in the U.S. with strong early international launch uptake, proving Merck's ability to diversify beyond oncology.
The subcutaneous formulation of Keytruda generated $463M in the quarter. This successful transition is critical for defending the franchise's market share ahead of the impending 2028 LOE.
🐻 Bear Case
Merck has spent nearly $15B in upfront one-time R&D charges across H1 2026 alone. While necessary for pipeline replenishment, these deals have turned a highly profitable business into a GAAP and non-GAAP loss-maker.
The diabetes portfolio (Januvia/Janumet) plummeted 31% YoY to $429M due to intense generic competition and pricing pressure, creating a massive drag on aggregate pharmaceutical growth.
⚖️ Verdict: ⚪
Neutral. Underlying operational performance is actually quite strong with Winrevair accelerating and Animal Health stable. However, the sheer magnitude of near-term EPS destruction from BD transactions masks the core profitability and makes the stock hard to own for earnings-focused investors.
Key Themes
Winrevair Trajectory is Accelerating
Winrevair continues to exceed expectations, posting $588M in sales, up from $525M in Q1 and $336M a year ago (+75% YoY). Management noted robust U.S. demand and early launch uptake in Japan and Europe. This asset is the undeniable cornerstone of Merck's cardio-pulmonary pillar and is rapidly mitigating the Keytruda concentration risk.
Keytruda Defense: The QLEX Transition is Working
The KEYTRUDA franchise grew 5% YoY to $8.36B, indicating stable growth. The crucial data point is the $463M contribution from KEYTRUDA QLEX (the subcutaneous formulation), up from $128M in Q1. Converting patients to this formulation is Merck's primary defense mechanism against the upcoming 2028 loss of exclusivity, and the early adoption curve is highly encouraging.
Animal Health Providing Durable Growth
Animal Health delivered a stable 8% YoY growth (5% ex-FX) to $1.77B. Both Livestock (+8%) and Companion Animal (+7%) segments participated. The BRAVECTO line specifically generated $359M (+7% YoY). This segment continues to act as a highly profitable, non-cyclical ballast for the broader company.
Diabetes Cliff is Decelerating Total Growth
The Januvia/Janumet franchise collapsed 31% YoY to $429M. This was expected due to generic competition in international markets and aggressive U.S. pricing pressure, but the absolute magnitude of the dollar decline ($194M wiped out YoY) forces newer products to work significantly harder just to keep the top-line flat.
Vaccine Portfolio Cannibalization & Pressure
While Gardasil stabilized with 4% YoY growth ($1.17B), returning from a severe China-driven shock in Q1, the broader pneumococcal portfolio is showing friction. VAXNEUVANCE fell a staggering 35% YoY to $148M. Management blamed lower U.S. public-sector demand and competitive pressures, but this also reflects cannibalization from Merck's own newly launched CAPVAXIVE ($184M). The net growth of the respiratory vaccine franchise is sputtering.
Cardiovascular Expansion: LIPFENDRA Approval
Merck secured FDA approval for LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor. Clinical data showed a ~59% reduction in LDL-C. This fundamentally shifts the PCSK9 market from injectables to oral daily dosing, placing Merck squarely in competition with Novartis and Amgen, and solidifying its cardiometabolic pipeline.
AI & Data Strategy Maturing
Management previously highlighted a multi-year partnership with Google Cloud and Tempus AI to accelerate precision oncology. The rapid pace of clinical trial readouts and target identification (like the Terns acquisition for MK-4208) reflects a strategy heavily leaning on external genomic and clinical datasets to improve R&D hit rates.
Other KPIs
Decelerating. Dropped from 82.2% in 25Q2. The 110 bps compression was driven primarily by inventory write-downs and higher amortization of intangible assets from recent acquisitions.
Accelerating drastically. Up from $4.05B a year ago. The entirety of this explosion is the $5.7B upfront charge for the Terns acquisition. Even adjusting for this, clinical development spending is rising as Merck pushes 80+ Phase 3 trials through the clinic.
Accelerating. Acquired via the Verona Pharma deal, this COPD asset generated $204M in Q2, up sequentially from $131M in Q1 and $178M in 25Q4. It is quickly establishing itself as a key pillar in the respiratory portfolio alongside Winrevair.
Guidance
Accelerating. Management narrowed and raised the range from the prior $65.8B-$67.0B, reflecting strong operational momentum in oncology and new launches. Midpoint implies roughly 3% YoY growth vs FY25.
Reversing downward. Drastically slashed from the prior guide of $5.04-$5.16. This 46% cut is not operational; it entirely reflects the $2.31 per share one-time charge for the Terns acquisition plus $0.12 in financing/advance costs. This adds to the $3.62 Cidara charge already absorbed.
Accelerating significantly from the prior 23.5%-24.5% guidance. The acquisitions of Cidara and Terns are non-tax-deductible, creating a massive upward distortion on the reported effective tax rate for the full year.
Accelerating. Raised significantly from prior $36.0B-$36.8B guidance. This exactly mirrors the $5.7B Terns charge sliding into the R&D expense line.
Key Questions
Terns Acquisition MMR Rates
During Q1, analysts flagged lower MMR achievement rates (2 out of 10) for TERN-701. Now that the $5.7B deal has closed, what incremental clinical data can you share that validates your confidence in the 'north of 50%' target you previously stated?
KEYTRUDA QLEX Conversion Dynamics
QLEX generated $463M this quarter. What is the current split of adoption between the U.S. and international markets, and what percentage of total Keytruda volume do you expect QLEX to capture by the end of FY26?
Pneumococcal Strategy
With VAXNEUVANCE dropping 35% YoY while CAPVAXIVE ramps up, are we seeing a pure 1-to-1 cannibalization, or are there distinct market segments where VAXNEUVANCE can maintain a floor?
Gardasil Run-Rate
Gardasil grew 4% YoY globally. Considering the halt of shipments to China earlier this year, does this Q2 figure represent the new normalized base run-rate, or is there still channel inventory to burn through in Asia-Pacific?